Aktas Samur, Anil http://orcid.org/0000-0002-0183-0562
Fulciniti, Mariateresa http://orcid.org/0000-0002-1432-9742
Avet-Loiseau, Herve
Lopez, Michael A.
Derebail, Sanika
Corre, Jill http://orcid.org/0000-0003-1580-6106
Minvielle, Stephane
Magrangeas, Florence
Moreau, Philippe
Anderson, Kenneth C. http://orcid.org/0000-0002-6418-0886
Parmigiani, Giovanni
Samur, Mehmet K. http://orcid.org/0000-0002-9978-5682
Munshi, Nikhil C. http://orcid.org/0000-0002-7344-9795
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (SPORE-P50CA100707, P01CA155258, SPORE-P50CA100707, P01CA155258, SPORE-P50CA100707, P01CA155258)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Paula and Rodger Riney foundation
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Health Services Research and Development (5I01BX001584)
Paula and Rodger Riney foundation grant
Article History
Received: 7 September 2022
Revised: 9 November 2022
Accepted: 22 November 2022
First Online: 20 December 2022
Competing interests
: KCA has received consulting fees from Pfizer, Amgen, AstraZeneca, Janssen, Precision Biosciences, and serves the board of directors of C4 Therapeutics, Oncopep, Mana, Raqia, Next RNA, Window, and Starton. NCM is a consultant for BMS, Janssen, Oncopep, Amgen, Pfizer, Karyopharm, Legend, NextRNA, Raqia, Abbvie, and Takeda, and GSK is on the board of directors of Oncopep. GP is a scientific co-founder of Phaeno Biotechnologies, serves on the Scientific Advisory Board of Ambry Genetics, and consults with Foundation Medicine and Delfi Diagnostics. The other authors have no other relevant conflicts of interest.